Relating patenting and peer-review publications: an extended perspective on the vascular health and risk management literature by Mucke, Hermann AM
© 2011 Mucke, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 265–272
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
265
ReView
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/VHRM.S14454
Relating patenting and peer-review publications: 
an extended perspective on the vascular health 
and risk management literature
Hermann AM Mucke
HM Pharma Consultancy,  
Vienna, Austria
Correspondence: Hermann AM Mucke 
HM Pharma Consultancy, Hutengasse 69, 
Vienna 1160, Austria 
Tel +43 664 101 0121 
Fax +43 664 77 101 0121 
email office@hmpharmacon.com
Purpose: This investigation identifies patent applications published under the international 
Patent Convention Treaty between July 2010 and January 2011 in three significant fields 
of vascular risk management (arterial hypertension, atherosclerosis, and aneurysms) and 
investigates whether the inventors have also published peer reviewed papers directly describing 
their claimed invention.
Results: Out of only 48 patent documents that specifically addressed at least one of the above-
mentioned fields, 15 had immediate companion papers of which 13 were published earlier 
than the corresponding patent applications; the majority of these papers were published by 
noncorporate patentees. Although the majority of patent applications (30 documents) had at 
least one corporate assignee, 18 came from academic environments. As expected, medical 
devices dominated in the aneurysm segment while pharmacology dominated hypertension and 
atherosclerosis.
Conclusion: Although information related to hypertension, atherosclerosis, or aneurysms 
that was claimed in international patent applications reached the public quicker through the 
corresponding peer review document if one was published, more than two-thirds of the patent 
applications had no such companion paper in a scientific journal. The patent literature, which 
is freely available online as full text, offers information to scientists and developers in the fields 
of vascular risk management that is not available from the peer reviewed literature.
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Introduction
There is no shortage of published information in the field of vascular risk management. 
In mid-February 2011, a PubMed search with the stringent term combination “blood 
vessels” [MeSH Terms] AND “risk management” [MeSH Terms] returned 3,603 hits, 
of which 535 had been published in 2010 or later; 600 were freely available as full 
text. These figures probably capture the majority of the PubMed-listed papers which 
have some degree of focus on vascular risk management, although an exact assessment 
of indexing precision is impossible because there is no single “correct” way to index 
a biomedical paper. (The current indexing practice in PubMed is a combination of 
MeSH terms provided by authors and those assigned by experienced human indexers 
at the National Library of Medicine, with algorithmic assistance).
However, neither the scientific journals that are included in the PubMed database 
nor the peer reviewed academic literature as a whole constitute a full representation 
of the public biomedical knowledge. A vast amount of information is published in 
the form of patent applications which are not peer reviewed according to scientific Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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criteria, but instead by a patent examiner. Moreover, the 
motivations for filing a patent application and for   submitting 
a manuscript for publication in a scientific journal differ 
substantially: while a paper is intended to offer data that 
allow new insights, a patent application is filed based on the 
expectation that the invention claimed therein could have 
practical applications within the next few years. This endows 
the “patent information universe” with an application-driven 
perspective instead of a science-oriented one, and therefore 
the patent record can potentially offer a very different 
  perspective on new developments.
The concepts of “novelty”, “obviousness”, and   “inventive 
content” are of central importance in patenting but their meaning 
in the framework of intellectual property is quite different 
from the way academic research commonly interprets them; 
rather, these terms are applied in a strictly defined legalistic 
fashion. For example, combining a particular antihypertonic 
drug and a particular diuretic can have “novelty”, even though 
members of the antihypertonic and diuretic drug classes have 
been combined for decades to treat hypertonia synergistically. 
The only proviso is that the particular combination being 
claimed as new has not been explicitly described prior to 
the filing date of the patent application (the priority date) 
in a fashion that makes it – in principle – accessible to the 
public, even if it has not been published in the academic sense. 
Even if the particular combination of drug species has been 
described earlier as being effective in treating hypertonia, a 
ratio between the compounds (or a dose) that is outside the 
previously described range can suffice for novelty. To carry 
the example further, “obviousness” is not defined by what 
a research cardiologist would view, but rather by what the 
“average knowledgeable person in the general field” (in this 
case, a pharmacologist with no research and development 
ambitions) could deduce by combining facts reported in the 
public “prior art” – without doing any experimental work.
On the other hand, any publicly available reference 
that predates the priority date of the patent application and 
describes the exact content of the claimed invention will 
negate novelty (and might create obviousness even if the 
description is not exact), and for this it does not have to appear 
in the academic or patent literature. For anybody who wants 
to have his or her work represented in both the academic 
and the intellectual property universe, it is essential to file 
the patent application before submitting the manuscript to a 
journal or making a congress presentation.
Using a comprehensive database of ophthalmological 
patent applications we have already reported case   studies 
that demonstrate how patents can either anticipate the 
appearance of information in the peer review literature, 
or else can contain information that is never published in 
  scientific journals.1 However, no systematic investigation had 
been undertaken at this time concerning whether inventions 
claimed in patent applications are also reported in the peer 
review literature. Such analyses of paired papers and patents 
in medical sciences are extremely scarce, and have mainly 
focused on the suspected restrictive influence of patenting 
on the dissemination of scientific information.2–4 The   present 
paper reports a pilot study that analyzes the most recent 
international patent application record in three major fields 
of relevance for vascular risk management (arterial hyper-
tension, atherosclerosis, and aneurysms), and relates this 
information to the peer review record as represented in the 
United States (US) National Library of Medicine’s PubMed 
literature database.
Materials and methods
The World Intellectual Property Organization’s Patent-
Scope database5 was searched for the keyword terms 
  “hypertension”, “atherosclerosis”, and “aneurysm” using 
date delimiters July 1, 2010 and January 31, 2011 and 
ignoring patent classification codes. Retrieved intellectual 
property documents were examined for their actual   specific 
content concerning the above subjects; documents that 
named these conditions without specifically dealing with 
the subject matter were discarded. For example,   documents 
that actually claimed drugs for treating diabetes and 
addressed hypertension and/or atherosclerosis only as 
diabetic   complications were omitted from consideration, 
as were documents claiming drugs for dyslipidemia that 
named atherosclerosis. Also, documents that referred only to 
new crystal forms or other minor physical modifications to 
known active agents were omitted, while documents claiming 
innovative new formulations were included.
For each identified patent document, PubMed was 
searched for papers published from the patent document 
priority date onward and naming at least one of the inventors 
as an author. If the patent content suggested MeSH terms 
or free-text keywords, an additional search was conducted 
based on these terms. PubMed hits were then examined 
based on their abstracts (and full texts if available) to identify 
“companion papers” to the respective patent documents. 
A peer review paper was considered a companion paper if 
it had at least one inventor as an author, and captured the 
scientific and/or technical essence of the patent document. 
(Note that a peer review paper with a content largely identical 
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filing date would invalidate the patent, therefore extending 
the PubMed search to earlier periods was not considered 
meaningful).
Results
Tables 1–3 present the key data of the identified international 
patent applications, and relate them to their companion peer 
review papers.
Hypertension: Of the 26 documents identified, 19 came 
from 16 different companies while seven had been filed by 
universities, hospitals, or foundations. The great majority 
(21 documents) concerned themselves with pharmaceuticals, 
while the remaining five dealt with biomarkers, surgical 
methods, or model algorithms. Only seven patent applica-
tions had direct peer review equivalents.
Atherosclerosis: Only eight patent applications were 
identified, with an even distribution between public and 
private assignees; six concerned pharmacological treatments; 
four had companion papers.
Aneurysm: Fourteen international patent documents, 
also with assignees evenly distributed between the corporate 
and noncorporate domains, were published during the 
period covered by our investigation; four had peer review 
equivalents. With the exception of three submissions 
claiming diagnostics, all were concerned with repair and 
stabilization devices. Five documents focused on cerebral 
aneurysms.
In total, 15 out of 48 patent applications had companion 
papers and 30 had at least one corporate assignee. Of the 15 
patent-paper pairs, nine were published by academic or foun-
dation inventors while six came from corporate inventors.
A closer look at the publication dates revealed that in all 
but two of those cases where a companion peer review paper 
had been published, it had appeared in print earlier than the 
corresponding patent document. This became even more 
pronounced if electronic publications ahead of print were 
included in the consideration (data not shown). Therefore a 
strong dichotomy resulted: while for the majority of patents 
the information was not available in peer review format at 
all, those cases where the information was also published in 
peer review journals tended to reach the public earlier in their 
peer reviewed versions. In several cases the paper preceded 
the corresponding patent by a year or more.
Discussion
Patent documents are very different from scientific jour-
nal papers in terms of intent, semantics, pre-publication 
critique, and publishing policy. The primary purpose 
of submitting a manuscript to an academic journal is to 
  communicate new scientific data and information concisely 
to a specialized audience of peers. At least two of these 
peers will anonymously review the manuscript and decide 
its fate according to the commonly accepted criteria of the 
scientific community.
In contrast, a patent is filed with the perspective of 
securing exclusivity of use with respect to future commercial 
applications and to strategically preserve the inventors’ and 
assignees’ competitive edge. The requirement for legally 
explicit statements frequently leads to the use of language 
that is considered repetitive, redundant, or outright trivial 
by the average scientist working in the respective field. 
Review is by a single, personally identified examiner who 
is not necessarily an expert in the particular field, and who 
conducts the review according to legally defined criteria 
without attempting an assessment of feasibility (such as, for 
example, whether a particular vascular repair device would 
make sense in clinical practice). Regardless of the result of 
this examination, every patent document is published within 
about 18 months of its filing date unless the submission is 
retracted.
Virtually every single one of these features of a patent 
document runs counter to what academic researchers in the 
life sciences or in medicine expect from a published paper. 
As a result, life scientists frequently ignore patents while 
researchers working in technical, engineering, or software 
development fields traditionally value them highly.
This analysis of patenting versus peer-review publishing 
in three major fields of vascular risk management shows 
that disregarding published patent documents as a source 
of novel information can severely limit researchers’ 
knowledge: 33 out of 48 documents had no direct equivalent 
in the peer review literature. Interestingly, this lack of 
matches was most pronounced in the field of hypertension 
which, as we had expected, had the most patent documents. 
However, there were a surprisingly low number of relevant 
patent documents identified overall so that conducting an 
actual comparative analysis for each field would not have 
been meaningful.
The analysis shows a dominance of corporate over 
academic and nonprofit organization assignees, however, 
the dominance is a relatively slight one (63%). The present 
investigation did not involve direct comparison with 
equivalent earlier periods, but analyses that are available 
for US patents show that allowing US universities to claim 
title to inventions that had been made with federal funding 
have dramatically increased academic representation in Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 1 international patent applications concerning arterial hypertension, July 2010 to January 2011
Patent number Assignee and  
country
Subject Published Companion  
paper
wO/2011/008001 CJ Cheiljedang (KR) Antihypertensive composition  
containing a ginsenosides enriched  
fraction of ginseng extract
January 20, 2011 None
wO/2011/004040 
wO/2011/004038
Universidad de Sevilla  
(eS)
Captopril or L-carnitine for controlling 
the cardiac inflammatory process that 
accompanies arterial hypertension
January 13, 2011 J Inflamm (Lond). 2010;7:21 
and J Physiol Biochem. 
2010;66(2):127–136
wO/2010/150921 Teijin Pharma (JP) A 2-phenylthiazole agent for  
hypertension or high-normal  
blood pressure
December 29, 2010 None
wO/2010/148411 entelos (US) Novel computer models of  
hypertension comprising a renin-
angiotensin-aldosterone system  
(RAAS) pathway module, a renal  
function module, and a blood  
pressure regulation module
December 23, 2010 None
wO/2010/146551 Ranbaxy Laboratories  
(iN)
Orally disintegrating compositions 
comprising angiotensin ii receptor 
antagonists for hypertensive crisis
December 23, 2010 None
wO/2010/143059 Generex Pharmaceuticals 
(CA)
Geum japonicum plant extracts for 
preventing or treating hypertension
December 16, 2010 None
wO/2010/142794 Bios international  
(iT)
Non-enzymatic in vitro method for 
detecting gp91phox as a marker  
of oxidative stress, including  
hypertension, atherosclerosis,  
cardiac hypertophy, and stroke
December 16, 2010 None
wO/2010/137336 Kowa (JP) Alpha-phenoxybenzeneacetic acid 
derivatives that are angiotensin ii  
receptor antagonists and PPARgamma 
agonists, for hypertension and  
metabolic syndrome
December 2, 2010 None
wO/2010/129379 Merck Sharpe and  
Dohme (US)
inhibitors of the Renal Outer  
Medullary Potassium (ROMK) channel 
(Kir1.1) with diuretic and natriuretic  
action for hypertension and chronic  
and acute heart failure
November 11, 2010 None
wO/2010/127096 Midwestern University  
(US)
Centhaquin and related adrenergic  
agents for treating hypertension, pain,  
and resuscitative hemorrhagic shock
November 4, 2010 None
wO/2010/124201 invasc Therapeutics  
(US)
Methylenedioxyphenyl ferulate, 
ferulylproline, and derivatives thereof as 
myeloperoxidase inhibitors and  
vasodilators for cardiovascular diseases
October 28, 2010 None
wO/2010/124120 Mercator Medsystems  
(US)
Minimally invasive surgery with local 
application of guanethidine into the 
adventitia to reduce the activity of the 
sympathetic nerves surrounding the  
renal artery, for the treatment of  
renal and arterial hypertension
October 28, 2010 None
wO/2010/119700 Kowa (JP) Dual angiotensin ii receptor antagonist  
and PPARgamma agonist, for  
hypertension and metabolic  
syndrome
October 21, 2010 None
wO/2010/116282 Pfizer (US) 4,5-Dihydro-1H-pyrazole  
mineralocorticoid receptor  
antagonists for diabetic nephropathy  
and hypertension
October 14, 2010 J Med Chem. 
2010;53(16):5979–6002
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Table 1 (Continued)
Patent number Assignee and  
country
Subject Published Companion  
paper
wO/2010/104721 eli Lilly (US) 5-((E)-(3-fluorodibenzo[b,e]oxepin-
11l(6H)-ylidene)methyl)-l-((7R,8aR)- 
hexahydro-1 H-pyrrolo [2,1-c][1,4] 
oxazin-7-yl)-1 H-benzo[d]imidazol- 
2(3H)-one, a mineralocorticoid  
receptor antagonist for kidney disease, 
hypertension, and heart failure
September 16, 2010 None
wO/2010/104646 Scott and white  
Memorial Hospital (US)
Simultaneous measurement of 
marinobufagenin and angiotensinogen  
in urine to differentiate volume  
extension and vasoconstrictive forms  
of hypertension
September 16, 2010 None
wO/2010/099054 Merck Sharpe and  
Dohme (US)
Soluble guanylate cyclase activators  
for endothelial dysfunction,  
atherosclerosis hypertension,  
and heart disease
September 2, 2010 None
wO/2010/096677 invasc Therapeutics  
(US)
Dinitroso-derivatives of dihydrolipoic  
acid for hypertension, myocardial 
infarction, stroke, atherosclerosis ect.
August 26, 2010 None
wO/2010/095462 Kowa (JP) 3-(5-Akoxypyrimidine-2-yl) pyrimidine-
4(3H)-one dual angiotensin ii receptor 
antagonist and PPARgamma agonist, for 
hypertension and metabolic syndrome
August 26, 2010 None
wO/2010/092811 Nihon University (JP) Biphenylcarboxamide compound for 
hypertension
August 19, 2010 None
wO/2010/088279 Cardiomems (US) wearable wireless blood pressure 
monitoring system with implanted  
sensor
August 5, 2010 None
wO/2010/084231 Fundació institut de  
Recerca de L’Hospital 
Universitari Vall  
d’Hebron (eS)
Kidney androgen-regulated protein  
(KAP) gene expression in renal tissue, 
for models to evaluate antihypertensive 
compounds
July 29, 2010 Circulation. 
2009;119(14):1908–1917
wO/2010/082367 Kikkoman (JP) Orally bioavailable angiotensin- 
converting enzyme (ACe)-inhibiting  
di- and tripeptides
July 22, 2010 J Agric Food Chem. 
2010;58(2):821–827
wO/2010/080183 University of Columbia  
(US)
Vasodilatory and anti-inflammatory  
soluble epoxide hydrolase inhibitors  
to treat hypertension
July 15, 2010 Bioorg Med Chem Lett. 
2009;19(8):2354–2359
wO/2010/078624 Vegenics (AU) Vascular endothelial growth factor  
(VeGF) C and D products for  
hypertension
July 15, 2010 Nat Med. 
2009;15(5):545–552
patenting during the following two decades.6 An analysis of 
the patenting and publishing data of 395 academic inventors 
from five major universities in Taiwan from 2002 to 2006 
suggested that patenting might increase the number and 
quality of papers published by these inventors.7
Although the absolute numbers are too low for actual 
statistics, the available data suggest that corporate inventors 
are less likely to publish their patented findings in scientific 
journals than nonprofit inventors. This was expected, since 
peer-review publishing is firmly rooted in academic culture 
while the standing of corporate scientists in the life sciences, 
or their companies, is not usually measured by such criteria. 
Patents are deemed far more important in this environment. 
If a 1987 analysis of 17 US pharmaceutical companies has 
demonstrated their patent data to represent an excellent 
indicator of overall corporate technological strength,8 there 
is little reason to assume that this situation has changed 
fundamentally. In addition, most patents that claim incre-
mental improvements over the prior art (eg, a new orally 
disintegrating tablet formulation for a particular compound, 
or a variation in the design of a vascular repair device) would 
not meet the criteria of “novelty” and “non-obviousness” Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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that are commonly applied in academic peer review, even if 
the claimed improvements might be immediately applicable 
and useful. In this context, a lack of companion peer review 
papers does not indicate poor relevance of a patent.
A very limited number of investigations have been 
published that discuss selected aspects of patenting in the 
context of the vascular risk factors that are the subject of 
this investigation.9–11 While these are important reviews that 
illustrate certain aspects, no analysis had been previously 
undertaken to relate such patenting activity with conjoined 
peer-review publishing.
This pilot study obviously has several limitations. First, 
since the latest patents included in this analysis were published 
only three weeks prior to the time of writing, more delayed 
peer review companion papers might be published as time 
progresses. However, the two post-patent peer review papers 
that this analysis did reveal appeared within a few weeks of the 
corresponding patent. Therefore it seems unlikely that many 
more true companion papers will be published for the patents 
listed in Tables 1–3. The delays involved in PubMed indexing of 
some peer review journals, which can amount to several months, 
constitute a potentially more severe limitation of this analysis, 
which covers the most recent 7 months of patenting related to 
innovation in vascular risk management. Studies that extend 
over longer periods of patenting and publishing, or compare 
several periods, could eventually provide more insight.
The data that are available now allow the conclusion that 
international patent applications can offer valuable insights 
into new developments concerning vascular risk manage-
ment which are not made available in academic peer-review 
publishing, at least not without a delay of many months which 
our limited study would not have consistently detected. This 
implies that systematic monitoring of the patent literature 
can potentially add a substantial amount of cutting edge 
information.
However, the obvious difficulty of the scientist having to 
negotiate the legalistic style and repetitive nature of patent 
jargon remains, as does the difficulty to identify relevant 
patents. While it has been argued that patent searching 
must become part of life science students’ information 
literacy instruction,12 a more pragmatic and encompassing 
approach could be algorithmically mapping patents to MeSH 
codes,13 which would allow integrated searches that cover 
both PubMed and open access patent databases. Although 
algorithmic parsing of typical “patent jargon” into semantics 
that are familiar to research scientists is only a dimly 
  perceived possibility at this time,14 text analysis has been 
able for some years to effectively identify innovative patents 
and provide ranking and mapping.15 For specialized applica-
tions such as the vascular risk management literature, expert 
systems might provide broadly deployable semi-automated 
solutions within the next few years.
Table 2 international patent applications concerning atherosclerosis, July 2010 to January 2011 (excluding antihyperlipidemic, antidiabetic, 
and nonspecific anti-inflammatory drugs)
Patent number Assignee and country Subject Published Companion paper
wO/2011/005608 Merck Sharpe and Dohme 
(US)
Cyclohexyl sulfonamide platelet- 
activating factor (PAF) receptor 
antagonists 
January 13, 2011 None
wO/2010/133662  iNSeRM (FR) interleukin-17 polypeptides for the 
prevention and treatment of 
atherosclerosis
November 25, 2010 Curr Opin Lipidol. 2010;21(5): 
404–408
wO/2010/126967 Boehringer ingelheim (De); 
New York University (US)
ex-vivo treatment of blood with 
protein kinase C-theta inhibitors 
for immunological diseases and 
atherosclerosis
November 4, 2010 Science. 2010;328(5976): 
372–376
wO/2010/108419 Chinese Academy of 
Medical Sciences (CN)
PON gene cluster to promote 
stability of atherosclerotic plaques
September 30, 2010 Circ Res. 2009;104(10): 
1160–1168
wO/2010/105285 Heart Research institute 
(AU)
Testing for atherosclerosis or a 
predisposition thereto, based on 
monocyte-derived endothelial cells
September 23, 2010 None
wO/2010/088455 General Hospital Corp. Cromolyn analogs to image and 
treat atherosclerotic plaques
August 5, 2010 None
wO/2010/079161 iNSeRM (FR) B cell depleting agent for the 
prevention or treatment of 
atherosclerosis
July 15, 2010 J Exp Med. 2010;207(8): 
1579–1578
wO/2010/077624 Merck Sharpe and Dohme 
(US)
Biaryl carboxamide PAF receptor 
antagonists 
July 8, 2010 NoneVascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 3 international patent applications concerning aneurysms, July 2010 to January 2011
Patent number Assignee and country Subject Published Companion paper
wO/2011/008906 Mayo Foundation (US) Automatic detection of cerebral  
aneurysms by assigning points of  
interest to raw image data files
January 20, 2011 J Digit Imaging. 2011;24(1): 
86–95
wO/2011/007352 Yissum R&D  
(Univ. of Jerusalem) (iL)
New endovascular aortic repair  
technique using a flexible  
endoprosthesis which stiffens at the  
implanation site
January 20, 2011 None
wO/2010/145703 GraftCraft i Göteborg  
AB (Se)
endovascular device for repair of a  
ruptured aneurysm, consisting of a  
balloon with a channel extending  
through it and a supporting blood-
permeable stent which remains in situ  
for 1–2 days postoperatively
December 23, 2010 None
wO/2010/134914 University of Miami (US) Spherical helix coils with shape memory  
to occlude cerebral aneurysms
November 25, 2010 J Med Device. 
2009;3(4):41005*
wO/2010/129270 Shriners Hospitals for  
Children; Pregon Health  
and Science University (US)
immunoassays to monitor disease 
progression in individuals with Marfan’s 
syndrome, aortic aneurysm, or  
scleroderma based on the  
concentration of circulating elastic fiber  
and microfibril fragments (fibrillin  
and fibulin)
November 11, 2010 None
wO/2010/127381 James Cook University  
(AU)
Altering levels of components in the 
kallikrein-kinin system to assist in  
preventing or treating aneurysms
November 11, 2010 None
wO/2010/123911 Lake Region Medical, inc.  
(US)
A tubular meshwork device with a  
patch to occlude the the neck of the 
aneurysm upon insertion, with exact  
axial and rotational positioning through  
a marker
October 28, 2010 None
wO/2010/123831 Chestnut Medical  
Technologies, inc. (US)
An occluding device that can be used to 
remodel an aneurysm within the vessel  
by neck reconstruction or balloon  
remodeling
October 28, 2010 Neurosurgery. 2009;64(4): 
632–642
wO/2010/120926 Chestnut Medical  
Technologies, inc. (US)
Occluding devices with adjustable  
porosity for tortuous vessels, especially  
of the neurovasculature, in proximity of 
oxygen-demanding tissues
October 21, 2010 Neurosurgery. 2009;64(4): 
632–642
wO/2010/112838 Barking Havering and  
Redbridge Hospitals (UK)
Multi-balloon catheter device for  
occlusion of aneurysms, with some  
balloons serving as deflectors for an  
occluding agent
October 7, 2010 None
wO/2010/110819 Arista Therapeutics, inc.  
(US)
improved implantable device  
containing and light-emitting diode  
(LeD) matrix to internally irradiate 
aneurysms
September 30, 2010 None
wO/2010/089491 A.L.N. (FR) intravascular device for occluding  
and aneurysm, consisting of a  
longitudinal, partially planar mesh  
skeleton covered with a film
August 12, 2010 None
wO/2010/082026 isis innovation Ltd. (UK) Stents for intracranial aneurysms,  
consisting of linked plates or rings  
arranged as a tube and deformable  
between an expanded state and a  
collapsed state
July 22, 2010 None
wO/2010/076838 individual inventor (iT) Catheter for a transcaval approach to  
an abdominal aneurysm
July 8, 2010 None
Note: *Same institution and subject, authors different from inventors.Vascular Health and Risk Management
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